{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-051485","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.286679+00:00","generated_at":"2026-06-08T19:02:19.615348+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GNI Group, controlling shareholder of Gyre Therapeutics, raises FY2023 forecast; revenue +3.9%, op profit +21.5%","bullets":["FY2023 revenue forecast raised to ¥26,267M (from ¥25,273M); operating profit to ¥7,280M (from ¥5,991M).","Net profit attributable to parent raised to ¥2,005M; basic EPS revised to ¥42.20 from ¥35.86.","ETUARY® sales in China exceeded expectations; Cullgen's Astellas alliance revenue above prior forecast.","Forex assumptions revised: US$1=¥138.24 and RMB1=¥19.62 (from ¥130.77 and ¥19.38).","Previous 2022 actuals: revenue ¥17,418M, net profit ¥388M, EPS ¥8.19."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-051485","json":"https://secwatch.observer/filing/0001140361-23-051485.json","markdown":"https://secwatch.observer/filing/0001140361-23-051485.md","text":"https://secwatch.observer/filing/0001140361-23-051485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051485/0001140361-23-051485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123051485/ny20009756x14_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:02:19.615348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}